The tweet was deleted by the author.
But we saved everything 🙂.
Corbus Pharmaceuticals Holdings, Inc. will present updated Phase 1/2 data for its CRB-701 program at the ASCO26 KOL event on June 1.
The event will feature clinical response durability and subgroup analyses, with expert discussions led by Ari Rosenberg, MD, HeadNeckMD, and Cesar A. Perez, MD. Participants are encouraged to register for the event to gain insights on the latest clinical advancements in head and neck squamous cell carcinoma (HNSCC) treatment from leading field experts.
Corbus previously outlined new clarity on CRB-701 Phase 1/2 trial data for oropharyngeal and cervical cancers. The company also announced plans to present updated Phase 1/2 trial results for CRB-701 at the 2026 ASCO annual meeting. Both updates focus on the ongoing clinical evaluation of CRB-701.